Navigation Links
Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
Date:6/8/2012

en versus placebo, and a larger effect in the patients not receiving chronic inhaled antibiotics. The effect of inhaled antibiotics was largely attributable to the use of inhaled aminoglycosides. In the intent to treat population, there was a 3% difference in the relative change from baseline in %-predicted FEV1 between the ataluren and placebo groups at Week 48 (-2.5% change on ataluren vs. -5.5% change on placebo; p=0.124). An analysis of the relative change from baseline in %-predicted FEV1 across all post-baseline study visits demonstrated an average difference between ataluren and placebo of 2.5% (-1.8% average change on ataluren vs. -4.3% average change on placebo; p= 0.0478).

The study was stratified for age, baseline FEV1, and the use of chronic inhaled antibiotics. A statistically significant effect (p=0.0072) was seen between treatment and use of inhaled antibiotics at baseline, indicating that inhaled antibiotics was a significant confounder of the overall results. A substantial treatment effect was seen in the patients not receiving chronic inhaled antibiotics at baseline; the Week 48 difference between the ataluren and placebo arms in FEV1 was 6.7% (-0.2% change on ataluren vs. -6.9% change on placebo).

The secondary endpoint, the rate of pulmonary exacerbations (ie, the number of pulmonary exacerbations in 48 weeks) also showed a positive trend in favor of ataluren, with the rate in the ataluren group being 23% lower than the placebo group (p=.0992). In the patients not receiving chronic inhaled antibiotics, the pulmonary exacerbation rate in the ataluren group was 43% lower than the rate in the placebo group. These results show a consistent treatment effect of ataluren on both pulmonary function and exacerbation rates. Mean relative change in %-predicted FEV1 (ITT population)Ataluren vs. PlaceboDifferencep-valueAll patients at Week 48
ataluren n=116; placebo n=116

3.0%

0.124All patients – averag
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
4. Sorrento Therapeutics Awarded Third Phase I STTR Grant
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
8. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
9. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
10. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
11. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... cold chain management app for smart shippers ... Magazine has included BioLife in its annual list of ... Washington state for 2015. Now in ...
(Date:7/2/2015)... 2, 2015 Legal-Bay LLC, The Lawsuit Settlement ... Joseph Goodwin in the Southern District of ... mesh cases against Ethicon for a single trial to ... for the 26 women include claims from the women ... my Johnson & Johnson,s Ethicon subsidiary. The cases against ...
(Date:7/1/2015)... , July 1, 2015 The Coalition ... of state and regional professional rheumatology societies, today ... rheumatologists that explored perceptions of biosimilars and the ... Biosimilars are medicines that are ... They are notably different from generic medications in ...
Breaking Medicine Technology:BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 3Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2
... N.J., Sept. 20 Princeton HealthCare System (PHCS) ( www.princetonhcs.org ... October 4, when it hosts a discussion about women,s pelvic ... program begins at 7 p.m. and can be joined by ... "Social media has enormous potential for sharing information ...
... and plant closure, the company still outpaces Advil in ... released today. The study showed that ... the same way they instinctively perceive and judge other ... and these judgments are highly predictive of brand purchase ...
Cached Medicine Technology:First Live Web Chat by New Jersey's Princeton HealthCare System Focuses on Women's Health 2Study of Brands Shows Tylenol Maintains Consumer Loyalty Despite Recent Quality Challenges 2
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... and Emerging Healthcare Delivery Coalition met for the late June Web-based session, the ... with new reimbursement schemes and managing high-risk patients through coordinated care. , During ...
(Date:7/2/2015)... Beach, CA (PRWEB) , ... July 02, 2015 ... ... surgical procedures and executing them with care and precision. There is an art ... FAACS, has had the honor of successfully reshaping the facial features and lives ...
(Date:7/2/2015)... , ... July 02, 2015 , ... ... (CVR) recently received nearly $4 million through five federal grants to study ... and therapies against the deadly diseases. , The research will be conducted ...
(Date:7/2/2015)... ... 02, 2015 , ... B. E. Smith, the only full-service ... a national chief executive officer recruitment for Indiana Blood Center in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of the Gelatin Capsule manufacturers. The report is a valuable source of guidance ... depicts the global and Chinese market for the Gelatin Capsule industry including capacity, ...
Breaking Medicine News(10 mins):Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 2Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 3Health News:ACO Coalition Discusses the Future of Medicare Payments and the Benefits of Providing More Care 4Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4
... When it comes to the attractiveness of orthodontic braces, ... The study of the public,s attitude about the attractiveness of ... appliances with no visible metal were considered the most attractive. ... clear wires were a less desirable option, and braces with ...
... WEDNESDAY, July 9 (HealthDay News) -- Being born extremely underweight ... as an adult. , A study published in the July ... were born at extremely low birth weights were more likely ... had been born at normal weights. , And that ...
... Reaches Out to Patients in Need of ... Care ... DaVita,Medical Missions(TM), a non-profit organization founded by DaVita Inc. that,focuses on bringing ... clinic in India in late,June. The new clinic is located in the ...
... U.S. Senate to vote soon on legislation that ... Minnesota, WASHINGTON, July 9 Seniors across ... Medicare Advantage program in,legislation being considered in the ... million from the Medicare Advantage program in,Minnesota alone ...
... the U.S. Senate,prepares to vote on legislation that would ... (AMA) is calling on Senators,to cast a yes vote ... In,June, the House passed the Medicare Improvements for Patients ... bipartisan vote of 355 to 59., "Last week, ...
... matinee, throughout U.S.,to debut film targeting Lazard CEO, ... residents from,controversial assisted living provider Atria Senior Living ... Thursday in a "rolling,matinee" to debut a new ... Films about Atria,s mistreatment of its workers and,elderly ...
Cached Medicine News:Health News:Survey: Most effective dental braces are least attractive 2Health News:Survey: Most effective dental braces are least attractive 3Health News:Do Underweight Newborns Make for Shy Adults? 2Health News:U.S. Non-Profit Brings Life-Saving Dialysis Treatment to India 2Health News:U.S. Non-Profit Brings Life-Saving Dialysis Treatment to India 3Health News:Minnesota Seniors Speak Out Against Medicare Advantage Cuts 2Health News:New Film Exposes Bruce Wasserstein and Lazard-linked Elderly Care Facilities Exploiting Seniors 2
... Articulating Tip Laryngoscopes are the ... Industry. The articulating tip aids ... an improved view of epiglottis. ... Optic styles. We guarantee your ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: